Holen Sie sich die Stockscreener-App
7.80
0.26%
0.02
Schlusskurs vom Vortag:
$7.78
Offen:
$7.73
24-Stunden-Volumen:
947.76K
Relative Volume:
0.75
Marktkapitalisierung:
$316.97M
Einnahmen:
$128.29M
Nettoeinkommen (Verlust:
$-30.69M
KGV:
-9.5122
EPS:
-0.82
Netto-Cashflow:
$-27.17M
1W Leistung:
-2.13%
1M Leistung:
-40.55%
6M Leistung:
-76.97%
1J Leistung:
-82.43%
1-Tages-Spanne:
$7.55
$7.915
1-Wochen-Bereich:
$7.55
$8.31
52-Wochen-Spanne:
$6.32
$58.23
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Vergleichen Sie RXST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.80 | 316.16M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
127.29 | 219.63B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.41 | 155.22B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
377.79 | 150.09B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
89.34 | 115.62B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.33 | 46.52B | 5.69B | 4.15B | 623.10M | 6.95 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
RXST LEGAL ALERT: Lose Money on Your RxSight, Inc. Investment? Contact BFA Law by September 22 Class Action Deadline (NASDAQ:RXST) - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Is Reminds Investors of Class - GlobeNewswire
RXST INVESTOR REMINDER: RxSight, Inc. Stock Drop Leads to - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages RxSight, Inc. - GlobeNewswire
RXST INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Investor Alert: Deadline Approaching to Join RxSight, Inc. (RXST) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Investigation into potential claims against RxSight, Inc. regarding securities class action. - AInvest
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming DeadlinesRXST - FinancialContent
RxSight, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before September 22, 2025 to Discuss Your RightsRXST - PR Newswire
Shareholders who lost money on their RxSight, Inc. (NASDAQ: - GlobeNewswire
Investors in RxSight, Inc. (RXST): Protect Your RightsContact Levi & Korsinsky Before September 22, 2025 - TradingView
Levi & Korsinsky Reminds RxSight, Inc. Investors of the - GlobeNewswire
Faruqi & Faruqi Reminds RxSight Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025RXST - ACCESS Newswire
RxSight, Inc. (RXST) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
RxSight Faces an Investors Lawsuit Over Growth Claims—Here’s What You Should Know - TradingView
Shareholders That Lost Money on RxSight, Inc. (RXST) Should Contact Levi & Korsinsky About Pending Class ActionRXST - The Globe and Mail
Investors in RxSight, Inc. Should Contact The Gross Law Firm Before September 22, 2025 to Discuss Your RightsRXST - MarketScreener
RxSight, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
RXST INVESTORS: RxSight, Inc. (NASDAQ:RXST) Investors may - GlobeNewswire
RXST LAWSUIT ALERT: The Gross Law Firm Notifies RxSight, - GlobeNewswire
CLASS ACTION NOTICE: Berger Montague Advises RxSight, Inc. (RXST) Investors to Inquire About a Securities Fraud Class Action - TradingView
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RXST Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the RxSight, Inc. Class Action - WV News
RXST INVESTORS: RxSight, Inc. (NASDAQ:RXST) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses - GlobeNewswire
Will RxSight Inc. outperform the marketLow Exposure Strategy with Sector Analysis - Newser
RXST INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WV News
Does RxSight Inc. fit your quant trading modelFree Smart Allocation Stock Pick Insights - Newser
Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - Morningstar
Shareholders that lost money on RxSight, Inc.(RXST) should contact Levi & Korsinsky about pending Class ActionRXST - Morningstar
The Cost of Deception: Analyzing RxSight's Securities Fraud and Market Impact - AInvest
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit - Morningstar
Berger Montague PC Investigates Investor Losses Related to RxSight, Inc. (RXST) Following Class Action Filing - TradingView
RXST LAWSUIT: RxSight, Inc. Sued for Fraud after LDD Sales - GlobeNewswire
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages RxSight, Inc. - GlobeNewswire
RXST Investors Have Opportunity to Lead RxSight, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Important Notice to Long-Term Shareholders of Alto - GlobeNewswire
RXST INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Newmont Sets a High Bar With Record Q2 Free Cash Flow: Will It Last? - The Globe and Mail
Will Higher Expected Costs Put a Dent in Kinross Gold's Margins? - The Globe and Mail
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky to Join Class Action Before September 22, 2025 - TradingView
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Class Action Alert: Levi & Korsinsky Reminds RxSight, Inc. (RXST) Investors of September 22, 2025 Deadline - ACCESS Newswire
RxSight (RXST) and the Risks of Healthcare Tech Volatility: A Deep Dive into Securities Fraud and Operational Collapse - AInvest
RXST INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that RxSight, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - WV News
Will RxSight Inc. stock split in the near futureFree Investment Portfolio Suggestions - Newser
Why RxSight Inc. stock attracts strong analyst attentionFree High-Accuracy Stock Picks - Newser
Class Action Filed Against RxSight, Inc. (RXST) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Securities Fraud in the Biotech Sector: Evaluating Risks and Governance Gaps at RxSight (RXST) - AInvest
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):